Y-mAbs Therapeutics's gross profit for the
three
months ended in Mar. 2024 was $17.78 Mil. Y-mAbs Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $73.02 Mil.
Y-mAbs Therapeutics had a gross margin of 89.23% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 8 years, the highestGross Margin % of Y-mAbs Therapeutics was 92.80%. The lowest was 86.41%. And the median was 88.90%.
Y-mAbs Therapeutics Gross Profit Historical Data
The historical data trend for Y-mAbs Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Y-mAbs Therapeutics's Gross Profit
For the Biotechnology subindustry, Y-mAbs Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's Gross Profit falls into.
Y-mAbs Therapeutics Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Y-mAbs Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $73.02 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Y-mAbs Therapeutics had a gross margin of 89.23% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Y-mAbs Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 